Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The impact of HPV genotypes on survival in HPV-positive oropharyngeal squamous cell carcinomas: a systematic review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{d04b5a05e0794b429c9129e7c199caa2,
title = "The impact of HPV genotypes on survival in HPV-positive oropharyngeal squamous cell carcinomas: a systematic review",
abstract = "BACKGROUND: Patients with HPV-positive (HPV+) oropharyngeal squamous cell carcinomas (OPSCCs) are known to have a better prognosis compared to patients with HPV-negative OPSCCs.AIMS/OBJECTIVES: To investigate the impact of specific HPV genotypes on survival in HPV + OPSCC.MATERIAL AND METHODS: A systematic search of PubMed and Embase for studies addressing the association between specific HPV genotypes and survival among patients with OPSCC was performed.RESULTS: Six studies (n = 1385 patients) published between 2013 and 2017 were included. Five studies (n = 1290 patients) found a better survival among HPV16 cases compared to other high-risk (HR) HPV genotypes (HPV 33, 18, 35, 31, 39, 52, 59, 45, 56, 67, 29, and 58), of which three studies (n = 933 patients) reached significant results. Two of these studies reported a five-year overall survival (OS) of 64.6% and 71.4% in HPV16 OPSCCs vs. 45.6% and 57.1% in HR non-HPV16 OPSCCs (p = .001 and p = .010, respectively), and the last study found a better OS among HPV16 cases with a hazard ratio (HR) of 0.35, 95%. CI [0.14;0.85], p = .02.CONCLUSIONS: Our findings indicate a favorable prognosis among patients with HPV16 OPSCC compared with HR non-HPV16 OPSCC. These results may be important when designing future trials and in the planning of follow-up regimes.",
keywords = "genotype, Human papillomaviurs, oropharyngeal squamous cell carcinoma, survival",
author = "Anne Skovvang and Jensen, {Jakob Schmidt} and Martin Garset-Zamani and Amanda Carlander and Christian Gr{\o}nh{\o}j and {von Buchwald}, Christian",
year = "2021",
month = jul,
doi = "10.1080/00016489.2021.1927173",
language = "English",
volume = "141",
pages = "724--728",
journal = "Acta Oto-Laryngologica",
issn = "0001-6489",
publisher = "Informa Healthcare",
number = "7",

}

RIS

TY - JOUR

T1 - The impact of HPV genotypes on survival in HPV-positive oropharyngeal squamous cell carcinomas

T2 - a systematic review

AU - Skovvang, Anne

AU - Jensen, Jakob Schmidt

AU - Garset-Zamani, Martin

AU - Carlander, Amanda

AU - Grønhøj, Christian

AU - von Buchwald, Christian

PY - 2021/7

Y1 - 2021/7

N2 - BACKGROUND: Patients with HPV-positive (HPV+) oropharyngeal squamous cell carcinomas (OPSCCs) are known to have a better prognosis compared to patients with HPV-negative OPSCCs.AIMS/OBJECTIVES: To investigate the impact of specific HPV genotypes on survival in HPV + OPSCC.MATERIAL AND METHODS: A systematic search of PubMed and Embase for studies addressing the association between specific HPV genotypes and survival among patients with OPSCC was performed.RESULTS: Six studies (n = 1385 patients) published between 2013 and 2017 were included. Five studies (n = 1290 patients) found a better survival among HPV16 cases compared to other high-risk (HR) HPV genotypes (HPV 33, 18, 35, 31, 39, 52, 59, 45, 56, 67, 29, and 58), of which three studies (n = 933 patients) reached significant results. Two of these studies reported a five-year overall survival (OS) of 64.6% and 71.4% in HPV16 OPSCCs vs. 45.6% and 57.1% in HR non-HPV16 OPSCCs (p = .001 and p = .010, respectively), and the last study found a better OS among HPV16 cases with a hazard ratio (HR) of 0.35, 95%. CI [0.14;0.85], p = .02.CONCLUSIONS: Our findings indicate a favorable prognosis among patients with HPV16 OPSCC compared with HR non-HPV16 OPSCC. These results may be important when designing future trials and in the planning of follow-up regimes.

AB - BACKGROUND: Patients with HPV-positive (HPV+) oropharyngeal squamous cell carcinomas (OPSCCs) are known to have a better prognosis compared to patients with HPV-negative OPSCCs.AIMS/OBJECTIVES: To investigate the impact of specific HPV genotypes on survival in HPV + OPSCC.MATERIAL AND METHODS: A systematic search of PubMed and Embase for studies addressing the association between specific HPV genotypes and survival among patients with OPSCC was performed.RESULTS: Six studies (n = 1385 patients) published between 2013 and 2017 were included. Five studies (n = 1290 patients) found a better survival among HPV16 cases compared to other high-risk (HR) HPV genotypes (HPV 33, 18, 35, 31, 39, 52, 59, 45, 56, 67, 29, and 58), of which three studies (n = 933 patients) reached significant results. Two of these studies reported a five-year overall survival (OS) of 64.6% and 71.4% in HPV16 OPSCCs vs. 45.6% and 57.1% in HR non-HPV16 OPSCCs (p = .001 and p = .010, respectively), and the last study found a better OS among HPV16 cases with a hazard ratio (HR) of 0.35, 95%. CI [0.14;0.85], p = .02.CONCLUSIONS: Our findings indicate a favorable prognosis among patients with HPV16 OPSCC compared with HR non-HPV16 OPSCC. These results may be important when designing future trials and in the planning of follow-up regimes.

KW - genotype

KW - Human papillomaviurs

KW - oropharyngeal squamous cell carcinoma

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85107732726&partnerID=8YFLogxK

U2 - 10.1080/00016489.2021.1927173

DO - 10.1080/00016489.2021.1927173

M3 - Review

C2 - 34101529

VL - 141

SP - 724

EP - 728

JO - Acta Oto-Laryngologica

JF - Acta Oto-Laryngologica

SN - 0001-6489

IS - 7

ER -

ID: 67742034